非小细胞肺癌原发灶与转移灶间的EGFR基因差异性研究进展

Research Advances in Heterogeneity of EGFR in Primary Tumor and Metastatic Sites of Non-small Cell Lung Cancer

非小细胞肺癌的发病率逐年上升,目前表皮生长因子受体(EGFR)酪氨酸激酶阻断剂广泛用于治疗非小细胞肺癌。非小细胞肺癌原发灶与转移灶对药物反应不一的现象逐渐受到重视,多数研究表明,两者的EGFR基因存在差异性,但不同研究结果的差异率亦不同;少数研究显示,两者的EGFR基因具有一致性。因此,目前对非小细胞肺癌原发灶与转移灶之间是否存在EGFR基因差异性尚不明确。

Non-small cell lung cancer （NSCLC）incidence is increasing year by year, and currently EGFR-TKI drugs are widely used in the treatment. Primary tumors and metastases reactions to the medication are diffetml,which is gradually drawing more attention. Most studies show that differences exist in EGFR gene of the primary and corresponding metastatic tumors, though the diftrence ratio of different research results arc different. Few studies show that EGFR gene are consistent between primary and corresponding metastatic tmnors. It is still unclear whether the EGFR genes III diseurdant between primary NSCLC and the currespnnding metastases.